Company profile: Clementia Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage, disease-modifying treatments for ultra-rare bone disorders and other debilitating diseases with high unmet medical need, including development of its lead product candidate, palovarotene, an oral small molecule.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Clementia Pharmaceuticals
Chiasma
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions developing oral drugs for orphan diseases using proprietary Transient Permeability Enhancer technology to convert approved injectables to oral formulations, potentially enabling new indications and enhanced absorption by promoting delivery to the GI wall and liver.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chiasma company profile →
Mereo Biopharma
HQ: United Kingdom
Website
- Description: Provider of UK-based specialty biopharmaceutical development and funding of novel, specialist-focused products sourced from large pharmaceutical and biotechnology companies. Portfolio includes Setrusumab for osteogenesis imperfecta, Alvelestat for AATD-associated lung disease, Etigilimab for advanced solid tumors, Navixizumab for post-platinum ovarian cancer, and Leflutrozole for hormonal disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mereo Biopharma company profile →
Cabaletta Bio
HQ: United States
Website
- Description: Provider of cell therapy solutions for B cell-mediated autoimmune diseases, leveraging clinically-validated and FDA-approved CAR T cell technology. Pipeline includes CABA-201, an investigational CD19 CAR T in RESET Phase 1/2 trials, a proprietary CABA platform, and CAART therapies targeting disease-causing B cells, including DSG3-CAART and MuSK-CAART for pemphigus vulgaris and myasthenia gravis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cabaletta Bio company profile →
Minoryx Therapeutics
HQ: Spain
Website
- Description: Provider of pharmacological chaperone small-molecule drugs for genetic, neurometabolic, and rare pediatric diseases. Develops leriglitazone, a selective PPAR gamma agonist for X-linked adrenoleukodystrophy and other CNS diseases, supported by phase 2/3 results. Programs include ADVANCE (adult X-ALD), NEXUS (pediatric cALD), CALYX (adult progressive cALD), and a Friedreich's ataxia proof-of-concept.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Minoryx Therapeutics company profile →
Aevi Genomic Medicine
HQ: United States
Website
- Description: Provider of research and development in genomic medicine focused on translating genetic discoveries into novel therapies, driven by a commitment to patients with pediatric onset life-altering diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aevi Genomic Medicine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Clementia Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Clementia Pharmaceuticals
2.2 - Growth funds investing in similar companies to Clementia Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Clementia Pharmaceuticals
4.2 - Public trading comparable groups for Clementia Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →